Fractures and Bone Mineral Density in Adult Women with 21-Hydroxylase Deficiency
The DOI matches its Crossref record; 39 of the 42 references it cites were found in a registry or an index.
Abstract
CONTEXT: Patients with classical congenital adrenal hyperplasia (CAH) receive lifelong, often supraphysiological, glucocorticoid therapy. Pharmacological doses of glucocorticoids are an established risk factor for osteoporosis. OBJECTIVE: Our objective was to evaluate bone mineral density (BMD), fracture prevalence, and markers of bone metabolism in adult females with CAH. DESIGN: This was a cross-sectional observational study. SETTING: Tertiary care referral centers were used in this study. PARTICIPANTS: We studied 61 women, aged 18-63 yr, with genetically verified CAH due to 21-hydroxylase deficiency. They were patients with salt wasting (n = 27), simple virilizing (n = 28), and nonclassical 21-hydroxylase deficiency (n = 6). A total of 61 age-matched women were controls. MAIN OUTCOME MEASURES: History of fractures was recorded. Total body, lumbar spine, and femoral neck BMD were measured by dual-energy x-ray absorptiometry. The World Health Organization criteria for osteopenia and osteoporosis were used. Serum marker of bone resorption, beta-C telopeptide was studied. RESULTS: The mean glucocorticoid dose in hydrocortisone equivalents was 16.9 +/- 0.9 mg/m2. Patients had lower BMD than controls at all measured sites (P < 0.001). In patients younger than 30 yr old, 48% were osteopenic vs. 12% in controls (P < 0.009). In patients 30 yr or older, 73% were osteopenic or osteoporotic vs. 21% in controls (P < 0.001). BMD was similar in the two classical forms and had no obvious relationship to genotypes. beta-C-telopeptide was decreased in older patients. More fractures were reported in patients than controls (P < 0.001). The number of vertebrae and wrist fractures almost reached significance (P = 0.058). CONCLUSIONS: Women with CAH have low BMD and increased fracture risk. BMD should be monitored, adequate prophylaxis and treatment instituted, and glucocorticoid doses optimized from puberty.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Using the WHO definition of reduced BMD 16, the prevalence of reduced BMD in previous CAH studies ranges between 45–60% 3, 4, 17 as compared to 52% in our cohort.”
From Cortical bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency (2015) · cites this paper as [4]
In the citing paper
“In contrast, a retrospective study of 62 adult women with CAH reported that chronic exposure to pharmacological GC doses may lead to bone loss accompanied by an increased incidence of fractures relative to healthy controls (264).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [264]
In the citing paper
“Bone density (total and medullary cross-sectional area) is increased in women with CAH with variably elevated serum testosterone (including into the male range) when it is only partially suppressed by glucocorticoid treatment (143), although more effective glucocorticoid suppression lowers bone density (144).”
From Circulating Testosterone as the Hormonal Basis of Sex Differences in Athletic Performance (2018) · cites this paper as [144]
Citations
Cites
Mazess, R., Barden, H., Bisek, J., & Hanson, J. (1990) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/51.6.1106 · Cited by 1,476 · cited 1×
“Whole body, lumbar spine (L2–L4), femoral neck BMD, body fat, and lean body mass were estimated by dual-energy x-ray absorptiometry (DXA) in 57 patients and 60 control subjects using a Lunar Model DPX-L or Prodigy equipment (Lunar Radiation, Madison, WI) using a standard procedure as previously described (23).”
MethodCongenital adrenal hyperplasia due to 21-hydroxylase deficiency*
White, P. C., & Speiser, P. W. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0398 · Cited by 1,432
New approaches for interpreting projected bone densitometry data
Professor Carter, D. R., Bouxsein, M. L., & Marcus, R. (1992) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650070204 · Cited by 1,065
Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency
White, P. C. (2000) · Endocrine Reviews · doi:10.1210/er.21.3.245 · Cited by 877
Clinical and Anthropometric Correlates of Bone Mineral Acquisition in Healthy Adolescent Girls*
KATZMAN, D. K., BACHRACH, L. K., CARTER, D. R., & MARCUS, R. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-6-1332 · Cited by 734 · cited 1×
“(26) to whole body measurements: BMAD BMC/(bone area(2): height).”
BackgroundCongenital adrenal hyperplasia.
Merke, D. P., & Bornstein, S. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66736-0 · Cited by 628
International Variations in Hip Fracture Probabilities: Implications for Risk Assessment
Kanis, J. A., Johnell, O., De Laet, C., Jonsson, B., Oden, A., & Ogelsby, A. K. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.7.1237 · Cited by 605
(2002) · Hormone Research in Paediatrics · doi:10.1159/000065490 · Cited by 458
Congenital Adrenal Hyperplasia: Is there an Effect on Penile Growth?
Levy, J. B., & Husmann, D. A. (1996) · The Journal of Urology · doi:10.1097/00005392-199608001-00060 · Cited by 415
Rudolph, A. M., Hoffman, J. I. E., & Rudolph, C. D. (1991) · Medical Entomology and Zoology · Cited by 336
Cited by
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
“Longterm observational studies have been somewhat informative (227, 228, 230, 231).”
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Congenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669
Circulating Testosterone as the Hormonal Basis of Sex Differences in Athletic Performance
Handelsman, D. J., Hirschberg, A. L., & Bermon, S. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00020 · Cited by 594
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Self-citationHealth status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients
Arlt, W., Willis, D. S., Wild, S. H., Krone, N., Doherty, E. J., Hahner, S., Han, T. S., Carroll, P. V., Conway, G. S., Rees, D. A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0917 · Cited by 506
“A singlecenter study in 55 adult women with classic CAH showed a high incidence of osteopenia and osteoporosis (27) and FIG.”
BackgroundPW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
Frisén, L., Nordenström, A., Falhammar, H., Filipsson, H., Holmdahl, G., Janson, P. O., Thorén, M., Hagenfeldt, K., Möller, A., & Nordenskjöld, A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0636 · Cited by 276
Self-citationGlucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy
Hardy, R. S., Zhou, H., Seibel, M. J., & Cooper, M. S. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00097 · Cited by 258
Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Pofi, R., Caratti, G., Ray, D. W., & Tomlinson, J. W. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad016 · Cited by 209
“Overall, BMD appears to be reduced at all skeletal sites in CAH, and, as for patients with Addison’s disease, this reduction correlates with cumulative GC exposure in some (289) but not all the studies (290).”
BackgroundHagenfeldt, K., Janson, P. O., Holmdahl, G., Falhammar, H., Filipsson, H., Frisen, L., Thoren, M., & Nordenskjold, A. (2008) · Human Reproduction · doi:10.1093/humrep/den118 · Cited by 205
“She discontinued metformin in early pregnancy and developed mild gestational diabetes during the last part of the pregnancy and was treated with insulin (Falhammar et al., 2007c).”
BackgroundMethodSelf-citationFalhammar, H., Frisén, L., Hirschberg, A. L., Norrby, C., Almqvist, C., Nordenskjöld, A., & Nordenström, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2093 · Cited by 204
Self-citationTASK channel deletion in mice causes primary hyperaldosteronism
Davies, L. A., Hu, C., Guagliardo, N. A., Sen, N., Chen, X., Talley, E. M., Carey, R. M., Bayliss, D. A., & Barrett, P. Q. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712000105 · Cited by 198
Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Falhammar, H., Frisén, L., Norrby, C., Hirschberg, A. L., Almqvist, C., Nordenskjöld, A., & Nordenström, A. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2957 · Cited by 196
“During the last decades the awareness of the long-term risks of the disease and its treatment have increased (1–3), with reports on cardiometabolic risk factors (6–14), decreased bone mineral density (10, 12, 14–17), and risk of fractures (15, 16), psychiatric morbidity (18), and affected quality of life (10, 19–24).”
BackgroundSelf-citationFalhammar, H., Nyström, H. F., Ekström, U., Granberg, S., Wedell, A., & Thorén, M. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0828 · Cited by 170
Self-citationNordenström, A., Frisén, L., Falhammar, H., Filipsson, H., Holmdahl, G., Janson, P. O., Thorén, M., Hagenfeldt, K., & Nordenskjöld, A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2639 · Cited by 161
Self-citationCongenital Adrenal Hyperplasia
Witchel, S. F., & Azziz, R. (2011) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2010.10.001 · Cited by 161
Nordenström, A., & Falhammar, H. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0712 · Cited by 158
Self-citationClinical perspectives in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency
Bulsari, K., & Falhammar, H. (2016) · Endocrine · doi:10.1007/s12020-016-1189-x · Cited by 149
Self-citationKoetz, K. R., Ventz, M., Diederich, S., & Quinkler, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2036 · Cited by 139
Nonclassic Congenital Adrenal Hyperplasia
Witchel, S. F., & Azziz, R. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/625105 · Cited by 101
Approach to the Adult with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency
Merke, D. P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2417 · Cited by 132
“Falhammer et al. ( 39 ) 61 females (55 classic, 18–63 yr) Osteopenia in 48% of patients 30 yr old, 73% of patients 30 yr old, and 21% of age-matched controls; patients had lower BMD than controls at all measured sites (P 0.001); more osteoporotic fractures (vertebrae, wrist, and hip) in patients vs. controls (P 0.058)”
BackgroundInfluentialManagement of adolescents with congenital adrenal hyperplasia
Merke, D. P., & Poppas, D. P. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70138-4 · Cited by 134
Falhammar, H., & Nordenström, A. (2015) · Endocrine · doi:10.1007/s12020-015-0656-0 · Cited by 127
Self-citationVerma, S., VanRyzin, C., Sinaii, N., Kim, M. S., Nieman, L. K., Ravindran, S., Calis, K. A., Arlt, W., Ross, R. J., & Merke, D. P. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03636.x · Cited by 126
Health Problems in Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency
Reisch, N., Arlt, W., & Krone, N. (2011) · Hormone Research in Paediatrics · doi:10.1159/000327794 · Cited by 106
Approach to the patient: the adult with congenital adrenal hyperplasia
Auchus, R. J., & Arlt, W. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1440 · Cited by 121
“Several studieshaveshownreducedbonemineral density in adults with 21OHD (9, 10).”
BackgroundYanase, T., Tajima, T., Katabami, T., Iwasaki, Y., Tanahashi, Y., Sugawara, A., Hasegawa, T., Mune, T., Oki, Y., Nakagawa, Y., et al. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0242 · Cited by 104
Leib, E. S., Saag, K. G., Adachi, J. D., Geusens, P., Binkley, N., McCloskey, E. V., & Hans, D. B. (2011) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2011.05.014 · Cited by 107
Clinical outcomes in the management of congenital adrenal hyperplasia
Falhammar, H., & Thorén, M. (2012) · Endocrine · doi:10.1007/s12020-011-9591-x · Cited by 106
Self-citationFalhammar, H., Filipsson Nyström, H., Wedell, A., & Thorén, M. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0877 · Cited by 103
Self-citationFalhammar, H., Butwicka, A., Landén, M., Lichtenstein, P., Nordenskjöld, A., Nordenström, A., & Frisén, L. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3707 · Cited by 98
Self-citationEthical Principles for the Management of Infants with Disorders of Sex Development
Gillam, L. H., Hewitt, J. K., & Warne, G. L. (2010) · Hormone Research in Paediatrics · doi:10.1159/000316940 · Cited by 97
Mazziotti, G., Formenti, A. M., Frara, S., Roca, E., Mortini, P., Berruti, A., & Giustina, A. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0154 · Cited by 96
Recommendations for treatment of nonclassic congenital adrenal hyperplasia (NCCAH): An update
Trapp, C. M., & Oberfield, S. E. (2012) · Steroids · doi:10.1016/j.steroids.2011.12.009 · Cited by 81
“glucocorticoids and degree of androgen excess/degree of control [57].”
BackgroundChakhtoura, Z., Bachelot, A., Samara-Boustani, D., Ruiz, J.-C., Donadille, B., Dulon, J., Christin-Maître, S., Bouvattier, C., Raux-Demay, M.-C., Bouchard, P., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0887 · Cited by 90
“(15); therefore, preventive methods might be introduced, including physical activity and diet-recommendations and vitamin D supplementation if necessary (48).”
BackgroundHealth status in 1040 adults with disorders of sex development (DSD): a European multicenter study
Falhammar, H., Claahsen-van der Grinten, H., Reisch, N., Slowikowska-Hilczer, J., Nordenström, A., Roehle, R., Bouvattier, C., Kreukels, B. P. C., Köhler, B., & _, _. (2018) · Endocrine Connections · doi:10.1530/ec-18-0031 · Cited by 76
Self-citationBone mineral density, bone markers, and fractures in adult males with congenital adrenal hyperplasia
Falhammar, H., Filipsson Nyström, H., Wedell, A., Brismar, K., & Thorén, M. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0865 · Cited by 82
Self-citationBiochemical and genetic diagnosis of 21-hydroxylase deficiency
Falhammar, H., Wedell, A., & Nordenström, A. (2015) · Endocrine · doi:10.1007/s12020-015-0731-6 · Cited by 80
Self-citationReduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency
Schulz, J., Frey, K. R., Cooper, M. S., Zopf, K., Ventz, M., Diederich, S., & Quinkler, M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1096 · Cited by 73
Al Alawi, A. M., Nordenström, A., & Falhammar, H. (2019) · Endocrine · doi:10.1007/s12020-018-01835-3 · Cited by 77
Self-citationMechanisms in endocrinology: endogenous subclinical hypercortisolism and bone: a clinical review
Chiodini, I., Vainicher, C. E., Morelli, V, Palmieri, S., Cairoli, E., Salcuni, A. S., Copetti, M., & Scillitani, A. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0289 · Cited by 73
Disorders of sex development: Summaries of long-term outcome studies
Schober, J. M., Nordenström, A., Hoebeke, P. B., Lee, P. A., Houk, C. P., Looijenga, L. H. J., Manzoni, G., Reiner, W. G., & Woodhouse, C. R. J. (2012) · Journal of Pediatric Urology · doi:10.1016/j.jpurol.2012.08.005 · Cited by 72
“BMD correlates negatively with cumulative dose and duration of treatment in CAH [16], less pronounced in women than men and potentially related to an increased osteoporotic fracture rate [17].”
BackgroundWebb, E. A., & Krone, N. P. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.04.002 · Cited by 72
“Exposure to high concentrations of glucocorticoids suppresses growth, increases blood pressure and can cause osteoporosis and iatrogenic Cushing’s syndrome (34,83,84,91,98).”
BackgroundSteroid 21 Hydroxylase Deficiency Congenital Adrenal Hyperplasia
Nimkarn, S., Lin‐Su, K., & New, M. I. (2011) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2011.07.012 · Cited by 67
46,XX DSD: the masculinised female
Auchus, R. J., & Chang, A. Y. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.11.001 · Cited by 67
Management considerations for the adult with congenital adrenal hyperplasia
Auchus, R. J. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.01.039 · Cited by 65
Bone Health in Disorders of Sex Differentiation
Bertelloni, S., Baroncelli, G., & Mora, S. (2010) · Sexual Development · doi:10.1159/000315961 · Cited by 64
“…but some of them investigated a possible difference between the 2 classical forms of CAH (simple virilizing and salt wasting) and found similar bone mass measurements in the 2 groups of patients [Hagenfeldt et al., 2000; Falhammar et al., 2007; Chakhtoura et al., 2008; Zimmermann et al., 2009].”
BackgroundResultInfluentialBilateral Adrenalectomy in Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis
MacKay, D., Nordenström, A., & Falhammar, H. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00217 · Cited by 59
“Sex Female 35 (73) 22 (85) 13 (59) Male 12 (25) 4 (15) 8 (36) Not specified 1 (2) 0 (0) 1 (5) Mean age, y 20 6 13 10 (5) 32 (10) Diagnosis 11OHD 7 (15) 3 (12) 4 (18) 21OHD 41 (85) 23 (88) 18 (82) SW 20 (42) 11 (42) 10 (45) SV 5 (10) 2 (8) 3 (14) Unspecified 16 (33) 10 (38) 5 (23) Indication for adrenalectomy Hyperandr…”
Self-citationRangaswamaiah, S., Gangathimmaiah, V., Nordenstrom, A., & Falhammar, H. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00493 · Cited by 59
“In our systematic review, two studies (36, 42) reported BMD corrected for height, two studies reported BMD corrected for BMI (35, 43) and the rest reported uncorrected BMD.”
BackgroundMethodResultInfluentialSelf-citationLong-Term Outcome of Patients With Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency
Mnif, M. F., Kamoun, M., Mnif, F., Charfi, N., Kallel, N., Naceur, B. B., Rekik, N. M., Abid, M., Mnif, Z., Sfar, M. H., et al. (2012) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31824369e4 · Cited by 54
El‐Maouche, D., Collier, S., Prasad, M., Reynolds, J. C., & Merke, D. P. (2015) · Clinical Endocrinology · doi:10.1111/cen.12507 · Cited by 53
Steroid 21 hydroxylase deficiency congenital adrenal hyperplasia
Nimkarn, S., Lin-Su, K., & New, M. I. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2009.08.001 · Cited by 52
Hardy, R., & Cooper, M. S. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.06.007 · Cited by 52
Challenges in treatment of patients with non-classic congenital adrenal hyperplasia
Adriaansen, B. P. H., Schröder, M. A. M., Span, P. N., Sweep, F. C. G. J., van Herwaarden, A. E., & der Grinten, H. L. C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1064024 · Cited by 51
Glucocorticoid-Induced Osteoporosis in Children with 21-Hydroxylase Deficiency
Ventura, A., Brunetti, G., Colucci, S. C., Oranger, A., Ladisa, F., Cavallo, L., Grano, M., & Faienza, M. F. (2012) · BioMed Research International · doi:10.1155/2013/250462 · Cited by 49
“[56] included 61 women with 21-OHD and 61 age-matched women as controls.”
BackgroundMethodResultInfluentialLong-Term Outcomes of Congenital Adrenal Hyperplasia
Nordenström, A., Lajić, S., & Falhammar, H. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1528 · Cited by 50
“Bone mineral density (BMD) has been reported to be anything from increased to decreased but most studies have found low BMD in at least one of the measured locations in both sexes and across all age groups [2,26,45-53].”
Self-citationAdrenal crises in older patients
Rushworth, R. L., Torpy, D. J., & Falhammar, H. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30122-4 · Cited by 48
Self-citationDaae, E., Feragen, K. B., Nermoen, I., & Falhammar, H. (2018) · Endocrine · doi:10.1007/s12020-018-1723-0 · Cited by 45
Self-citationZimmermann, A., Sido, P. G., Schulze, E., Al Khzouz, C., Lazea, C., Coldea, C., & Weber, M. M. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03518.x · Cited by 45
Reisch, N. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0820-2085 · Cited by 36
“Some studies even reported an increased fracture risk [48].”
BackgroundSchaeffer, T. L., Tryggestad, J. B., Mallappa, A., Hanna, A., Krishnan, S., Chernausek, S. D., Chalmers, L. J., Reiner, W. G., Kropp, B. P., & Wisniewski, A. B. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/692439 · Cited by 45
“Observations of lower BMD, as well as increased occurrence of fractures, exist for women with CAH [59].”
BackgroundNermoen, I., Brønstad, I., Fougner, K. J., Svartberg, J., Øksnes, M., Husebye, E. S., & Løvås, K. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0196 · Cited by 43
Iodine-deficiency prophylaxis and the restriction of salt consumption - a 21st century challenge.
Szybiński, Z., Jarosz, M. J., Hubalewska–Dydejczyk, A., Stolarz-Skrzypek, K., Kawecka−Jaszcz, K., Traczyk, I., & Stos, K. (2010) · PubMed · Cited by 44
Voice characteristics in women with congenital adrenal hyperplasia due to 21‐hydroxylase deficiency
Nygren, U., Södersten, M., Falhammar, H., Thorén, M., Hagenfeldt, K., & Nordenskjöld, A. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03347.x · Cited by 43
Self-citationFalhammar, H., Nyström, H. F., & Thorén, M. C. (2014) · Endocrine · doi:10.1007/s12020-013-0161-2 · Cited by 43
Self-citationFalhammar, H., Frisén, L., Hirschberg, A. L., Nordenskjöld, A., Almqvist, C., & Nordenström, A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab712 · Cited by 42
Self-citationCeccato, F., Barbot, M., Albiger, N., Zilio, M., De Toni, P., Luisetto, G., Zaninotto, M., Greggio, N. A., Boscaro, M., Scaroni, C., et al. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0104 · Cited by 42
Riehl, G., Reisch, N., Roehle, R., Claahsen van der Grinten, H., Falhammar, H., & Quinkler, M. (2020) · Clinical Endocrinology · doi:10.1111/cen.14149 · Cited by 39
Self-citationGuidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision)
Ishii, T., Anzo, M., Adachi, M., Onigata, K., Kusuda, S., Nagasaki, K., Harada, S., Horikawa, R., Minagawa, M., Minamitani, K., et al. (2015) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.24.77 · Cited by 44
“BMD decreased in adults ≥ 30 yr old and in postmenopausal females with 21-OHD (123), but BMD did not decrease in comparison with controls in pubertal children and young adults with 21-OHD (124).”
BackgroundResultPrednisolone is associated with a worse bone mineral density in primary adrenal insufficiency
Frey, K. R., Kienitz, T., Schulz, J., Ventz, M., Zopf, K., & Quinkler, M. O. (2018) · Endocrine Connections · doi:10.1530/ec-18-0160 · Cited by 38
Li, L., Bensing, S., & Falhammar, H. (2021) · Endocrine · doi:10.1007/s12020-021-02723-z · Cited by 37
Self-citationFALHAMMAR, H., FILIPSSON, H., HOLMDAHL, G., JANSON, P.-O., NORDENSKJÖLD, A., HAGENFELDT, K., & THORÉN, M. (2009) · Endocrine Journal · doi:10.1507/endocrj.k08e-312 · Cited by 35
Self-citationSarafoglou, K., Merke, D. P., Reisch, N., der Grinten, H. L. C., Falhammar, H., & Auchus, R. J. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad134 · Cited by 35
Self-citationAuer, M. K., Paizoni, L., Hofbauer, L. C., Rauner, M., Chen, Y., Schmidt, H., Huebner, A., Bidlingmaier, M., & Reisch, N. (2020) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2020.105734 · Cited by 33
“Data on bone metabolism is limited and heterogeneous, with different studies indicating decreased bone formation but normal resorption [6], decrease of both markers of bone formation and resorption [16], and others, an increase in markers of bone formation and resorption 17].”
Congenital adrenal hyperplasia in adults
Auchus, R. J. (2010) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32833961d7 · Cited by 30
Kim, J. H., Choi, S., Lee, Y. A., Lee, J., & Kim, S. G. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1328 · Cited by 33
“Women with CAH had lower BMD and higher osteoporotic fracture risk than controls [27].”
BackgroundMooij, C. F., Webb, E. A., Claahsen van der Grinten, H. L., & Krone, N. (2017) · Archives of Disease in Childhood · doi:10.1136/archdischild-2016-311910 · Cited by 31
Factors impacting on the action of glucocorticoids in patients receiving glucocorticoid therapy
Dineen, R., Stewart, P. M., & Sherlock, M. (2019) · Clinical Endocrinology · doi:10.1111/cen.13837 · Cited by 30
Long‐term health consequences of congenital adrenal hyperplasia
Pofi, R., Ji, X., Krone, N. P., & Tomlinson, J. (2023) · Clinical Endocrinology · doi:10.1111/cen.14967 · Cited by 30
“154 These data endorses previous studies that have demonstrated a direct relationship between DHEAS concentrations 139,147,150 and androstenedione ‐ to ‐ testosterone ratio 146 with BMD in adults with CAH.”
Russian clinical practice guidelines «congenital adrenal hyperplasia»
Mokrysheva, N. G., Mel'nichenko, G. A., Adamyan, L. V., Troshina, E. A., Молашенко, Н. В., Игоревна, С. А., Uvarova, E. V., Esayan, E. R. M., Andreeva, E. N., Ужегова, Ж. А., et al. (2021) · Obesity and metabolism · doi:10.14341/omet12787 · Cited by 30
Bachelot, A., Chakhtoura, Z., Samara-Boustani, D., Dulon, J., Touraine, P., & Polak, M. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/326275 · Cited by 21
Kocova, M., Anastasovska, V., & Falhammar, H. (2020) · Endocrine · doi:10.1007/s12020-020-02323-3 · Cited by 24
Self-citationSubstitution therapy in adult patients with congenital adrenal hyperplasia
Reisch, N. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.11.002 · Cited by 24
Management of the Adult with Congenital Adrenal Hyperplasia
Auchus, R. J. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/614107 · Cited by 17
“Reduced bone mineral density has been found in 21-OHD in most studies [35, 36], but the degree is moderate, and frank osteoporosis is uncommon.”
Congenital adrenal hyperplasia
Demirci, C., & Witchel, S. F. (2008) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2008.00216.x · Cited by 24
“Among Swedish women with CAH, the frequency of osteopenia and osteoporosis was increased irrespective of age group, clinical phenotype, molecular genotype, and height compared to healthy age-matched control women (47).”
BackgroundΜacut, D., Zdravković, V., Bjekić-Macut, J., Mastorakos, G. P., & Pignatelli, D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00681 · Cited by 21
“Apart from the more pronounced decrease in BMD after the age of 30, an increased rate of osteoporotic fractures was shown in women with classic CAH treated with GCS (71).”
BackgroundResultNygren, U., Nyström, H. F., Falhammar, H., Hagenfeldt, K., Nordenskjöld, A., & Södersten, M. (2013) · Clinical Endocrinology · doi:10.1111/cen.12226 · Cited by 21
Self-citationSarafoglou, K., Gonzalez‐Bolanos, M. T., Zimmerman, C. L., Boonstra, T., Yaw Addo, O., & Brundage, R. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.424 · Cited by 20
Defects of Adrenal Steroidogenesis
Yau, M., Khattab, A., Pina, C., Yuen, T., Meyer‐Bahlburg, H. F. L., & New, M. I. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00104-9 · Cited by 20
Choi, J., & Yoo, H. (2017) · Korean Journal of Pediatrics · doi:10.3345/kjp.2017.60.2.31 · Cited by 17
Engberg, H., Nordenström, A., & Hirschberg, A. (2025) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/clinem/dgae696 · Cited by 8
Loli, P., Menotti, S., di Filippo, L., & Giustina, A. (2025) · Endocrine · doi:10.1007/s12020-025-04341-5 · Cited by 16
Matthews, D., & Cheetham, T. D. (2013) · Clinical Endocrinology · doi:10.1111/cen.12065 · Cited by 15
Righi, B., Ali, S., Bryce, J., Tomlinson, J., Bonfig, W., Baronio, F., Costa, E. C., Guaragna‐Filho, G., T'Sjoen, G. G., Cools, M., et al. (2023) · Endocrine · doi:10.1007/s12020-023-03330-w · Cited by 15
Self-citationDelvecchio, M., Soldano, L., Lonero, A., Ventura, A., Giordano, P., Cavallo, L., Grano, M., Brunetti, G., & Faienza, M. F. (2014) · Endocrine · doi:10.1007/s12020-014-0332-9 · Cited by 15
Congenital adrenal hyperplasia: New biomarkers and adult treatments
Dreves, B., Reznik, Y., & Tabarin, A. (2023) · Annales d Endocrinologie · doi:10.1016/j.ando.2023.01.008 · Cited by 15
Auer, M. K., Krumbholz, A., Bidlingmaier, M., Thieme, D., & Reisch, N. (2019) · Neuroendocrinology · doi:10.1159/000504672 · Cited by 14
Defects of Adrenal Steroidogenesis
Wajnrajch, M. P., & New, M. I. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00103-9 · Cited by 13
DEMİREL, F., Kara, Ö., Tepe, D., & Esen, İ. (2013) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1301-114 · Cited by 13
Metadata
- Authors
- Falhammar, H., Filipsson, H., Holmdahl, G., Janson, P.-O., Nordenskjöld, A., Hagenfeldt, K., & Thorén, M.
- Affiliations
- Karolinska University Hospital (SE)
- Departments of Endocrinology (H.Fi.), Sahlgrenska University Hospital and Sahlgrenska Academy, SE-413 45 Gothenburg, Sweden
- Sahlgrenska University Hospital (SE)
- Departments of Paediatric Surgery (A.N.), Karolinska University Hospital and Karolinska Institute, SE-171 76 Stockholm, Sweden
- Departments of Molecular Medicine and Surgery (H.Fa., A.N., M.T.), Karolinska University Hospital and Karolinska Institute, SE-171 76 Stockholm, Sweden
- Corresponding author
- Falhammar, Henrik
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2007-12-01
- Volume
- 92
- Issue
- 12
- Pages
- 4643-4649
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2095652975
- Cited by
- 151
- References
- 42
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 2 · 2023: 10 · 2022: 7 · 2021: 8 · 2020: 10 · 2019: 8 · 2018: 11 · 2017: 5 · 2016: 8 · 2015: 8 · 2014: 11 · 2013: 7 · 2012: 9
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Vetenskapsrådet
- Göteborgs Läkaresällskap
- Magnus Bergvalls Stiftelse
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- 21-hydroxylase deficiency, congenital adrenal hyperplasia, bone mineral density, fracture, osteoporosis, osteopenia, glucocorticoid therapy, cortisol, bone resorption, women, salt wasting, fracture risk
- MeSH terms
- Adrenal Hyperplasia, Congenital, Adult, Bone and Bones, Female, Genotype, Glucocorticoids, Hormones, Humans, Mutation, Osteoporosis, Parathyroid Hormone, Steroid 21-Hydroxylase, Cohort Studies, Biomarkers, Bone Density, Collagen Type I, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.